This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: IgG geneexpressing animal models. Regeneron Pharmaceuticals is the leading patent filer in IgG geneexpressing animal models.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Protein that manipulates geneexpression inside the cell nucleus could inspire new RSV drugs, vaccines.Protein that manipulates geneexpression inside the cell nucleus could inspire new RSV … Continue reading →
Gene therapy, which was in its infancy around 30 years ago, is now becoming a more prominent treatment method in many therapeutic areas, from personalized therapy to mass vaccinations against COVID-19. GeneExpression Considerations.
Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. BacTRL Gene Therapy Platform.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.
XTALKS WEBINAR: Measuring Intact mRNA and 5’ Capping Efficiency in One Assay Live and On-Demand: Thursday, October 17, 2024 , at 12pm EDT ( 9am PDT ) Register for this free webinar to learn about a multiplexed imaging platform that is engineered to address needs in mRNA and vaccine drug product characterization.
In a field quickly gaining attention for its role in vaccine development and personalized medicine, Elixirgen Therapeutics stands out through its pursuit of innovation and safety. Founded in Baltimore, Maryland, a vibrant science hub, Elixirgen Therapeutics emerged from a vision to harness the untapped potential of mRNA technology.
Omega’s platform is designed to adjust geneexpression to healthy levels rather than switching genes on and off. The work of the company is based on the genes and their regulatory elements found in loops of DNA called Insulated Genomic Domains (IGDs).
In his laudatory speech, Werner Baumann, Chairman of the Board of Management of Bayer, emphasized the importance of science and transparency in research: “In record time – much quicker than even the most optimistic observers dared to hope – scientists were able to develop various vaccines against the virus. In the Chemistry category Dr.
Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence geneexpression, respectively. RNA interference (RNAi) Therapeutics : Fundamentally, RNAi is a natural process of post-transcriptional gene silencing, involving short strands of nucleic acids.
With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally.
CureVac and the University Medical Center of Mainz launched a Phase III trial of CVnCoV, their COVID-19 vaccine candidate, in healthcare workers. The study will evaluate the safety and immunogenicity of the vaccine in a two-dose schedule of 12 micrograms.
Xtalks spoke to lead author on the study, Mohamed Abdel-Mohsen, PhD, assistant professor, Vaccine & Immunotherapy Center at the Wistar Institute, about the emerging utility of identifying glycomic, or sugar, signatures on the surface of immune cells to help in their identification and potential targeting.
From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it.
It’s because certain genes act one way on some people… and another way on other people. Putting this in medical jargon, the gene ‘expresses’ one way with Bob, for example, and a completely different way with Mary. How a geneexpresses – that is, how the gene affects you – goes on to determine whether you get ill or not.
Opiate-like effects of sugar on geneexpression in reward areas of the rat brain. Hormones (Athens). 2014 Oct-Dec;13(4):458-75. DOI: 10.14310/ horm.2002.1551. 2002.1551. . Spangler R, Wittkowski KM, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. Brain Res Mol Brain Res. 2004 May 19;124(2):134-42. DOI: 10.1016/j.molbrainres.2004.02.013
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content